Insider Selling: Integer Holdings Co. (NYSE:ITGR) Director Sells $1,175,791.32 in Stock

Integer Holdings Co. (NYSE:ITGR) Director James F. Hinrichs sold 9,603 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $122.44, for a total value of $1,175,791.32. Following the completion of the sale, the director now owns 7,424 shares in the company, valued at $908,994.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Integer Stock Up 0.1 %

Shares of ITGR opened at $121.63 on Friday. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of 42.09, a PEG ratio of 1.79 and a beta of 1.12. Integer Holdings Co. has a 52 week low of $69.40 and a 52 week high of $123.99. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.01 and a current ratio of 3.32. The business’s fifty day moving average price is $116.38 and its two-hundred day moving average price is $106.05.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. Integer had a return on equity of 11.25% and a net margin of 6.01%. The firm had revenue of $414.80 million during the quarter, compared to analyst estimates of $412.78 million. During the same period last year, the company earned $0.87 earnings per share. The company’s revenue was up 9.5% on a year-over-year basis. On average, analysts predict that Integer Holdings Co. will post 5.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ITGR shares. Benchmark reiterated a “buy” rating and issued a $130.00 price target on shares of Integer in a research report on Friday, May 10th. Citigroup lifted their target price on shares of Integer from $118.00 to $124.00 and gave the company a “neutral” rating in a research note on Wednesday, May 22nd. CL King initiated coverage on Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 price target on the stock. KeyCorp lifted their price objective on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th. Finally, Bank of America raised Integer from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $128.00.

Hedge Funds Weigh In On Integer

Several large investors have recently bought and sold shares of the business. North Growth Management Ltd. acquired a new position in shares of Integer in the 4th quarter valued at $9,155,000. GSA Capital Partners LLP bought a new position in Integer during the third quarter worth about $816,000. Dark Forest Capital Management LP boosted its holdings in Integer by 69.8% during the third quarter. Dark Forest Capital Management LP now owns 11,984 shares of the medical equipment provider’s stock worth $940,000 after buying an additional 4,926 shares during the last quarter. Legacy Wealth Asset Management LLC acquired a new position in shares of Integer during the 4th quarter worth about $239,000. Finally, Quadrant Capital Group LLC increased its stake in shares of Integer by 10.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 132 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.